TLDR
- PSTV drops 5% despite REYOBIQ posting over 75% benefit in LM trial.
- REYOBIQ impresses at SITC 2025, but PSTV stock trades lower on the day.
- Plus Therapeutics shares slide even with strong REYOBIQ clinical updates.
- CNS cancer data shines, yet PSTV ends red after SITC 2025 presentation.
- PSTV fails to rally as REYOBIQ earns spotlight at immunotherapy summit.
Plus Therapeutics, Inc. (PSTV) shares opened higher early morning but reversed sharply, ending down nearly 5% at $0.5166.
Plus Therapeutics, Inc., PSTV
The stock showed no strong recovery through midday, and momentum remained weak as sentiment leaned heavily bearish. This occurred even as the company spotlighted positive REYOBIQ trial data at the 40th SITC Annual Meeting.
REYOBIQ Phase 1 Results Showcase Strong Clinical Benefit Rate
Plus Therapeutics presented REYOBIQ data from its ReSPECT-LM Phase 1 trial at the SITC 2025 conference on November 9 in Alexandria, VA. The trial showed a clinical benefit rate over 75% across three key outcome metrics for patients with leptomeningeal metastases. This high response rate demonstrated consistent treatment impact in a patient group facing limited therapeutic options.
The company emphasized that no dose-limiting toxicities were reported at any dose level during the trial phase. RNA sequencing data and circulating tumor cell reduction pointed to measurable tumor cell death. These biological indicators support REYOBIQ’s activity and strengthen its clinical profile.
The trial safely escalated dosing to 44.1 mCi, which has been set as the recommended Phase 2 level. This suggested REYOBIQ’s therapeutic potential at higher doses than the current standard of care. The data backed its FDA Fast Track and Orphan Drug designations, which remain in place.
SITC 2025 Conference Highlights CNS Cancer Innovations
Dr. Andrew Brenner from the University of Texas Health Science Center presented the REYOBIQ clinical results at the SITC event. His session focused on advanced therapies targeting leptomeningeal metastases, a condition with no currently approved treatments. The company’s participation highlighted its ongoing leadership in central nervous system oncology.
The SITC 2025 meeting brought global experts to discuss novel immunotherapies and radiotherapeutic strategies for brain metastases. Plus Therapeutics used the platform to reinforce confidence in its expanding REYOBIQ program. The presentation drew attention due to the significant unmet need and the potential clinical impact of the therapy.
While REYOBIQ was the focus, the company also noted ongoing enrollment for the ReSPECT-LM Dose Optimization Trial. This extension aims to refine treatment precision and therapeutic index further. Plus Therapeutics continues pushing for broader clinical validation through expanded trial phases.
PSTV Stock Trades Lower Despite Strong Development Pipeline
Despite the promising REYOBIQ results, PSTV stock failed to sustain early gains and fell throughout the trading session. The stock faced resistance, and selling pressure built up after the morning spike ended around 7:00 AM. Traders showed limited reaction to the clinical data presented at SITC.
The drop came amid broader market uncertainty and weak volume patterns in small-cap biotech names. Although REYOBIQ data showed measurable progress, the stock lacked catalysts to sustain upward momentum. PSTV trading ended near session lows, with no meaningful recovery attempts seen during the afternoon.
Plus Therapeutics continues advancing its targeted radiotherapeutics for CNS cancers while expanding clinical trial participation. The company maintains its FDA designations and support for REYOBIQ across multiple clinical fronts. PSTV remains under pressure, with sentiment cautious despite a strong scientific narrative.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
